Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1894 1
1896 1
1925 1
1926 1
1928 1
1929 1
1932 2
1933 1
1934 2
1935 2
1936 2
1937 1
1945 1
1946 8
1947 16
1948 16
1949 13
1950 31
1951 37
1952 30
1953 60
1954 52
1955 77
1956 80
1957 69
1958 68
1959 68
1960 76
1961 84
1962 112
1963 172
1964 237
1965 190
1966 207
1967 246
1968 256
1969 274
1970 273
1971 289
1972 278
1973 313
1974 263
1975 270
1976 299
1977 253
1978 231
1979 287
1980 259
1981 262
1982 342
1983 304
1984 376
1985 435
1986 467
1987 563
1988 569
1989 740
1990 820
1991 843
1992 849
1993 1096
1994 1123
1995 1178
1996 1268
1997 1519
1998 1634
1999 1753
2000 2006
2001 2178
2002 2446
2003 2613
2004 2948
2005 3200
2006 3215
2007 3190
2008 3362
2009 3496
2010 3685
2011 4039
2012 4111
2013 4252
2014 4401
2015 4632
2016 4629
2017 4700
2018 4856
2019 4848
2020 3942
Text availability
Article attribute
Article type
Publication date

Search Results

90,024 results
Results by year
Filters applied: . Clear all
Page 1
Management of severe osteoporosis.
Miller PD. Miller PD. Expert Opin Pharmacother. 2016;17(4):473-88. doi: 10.1517/14656566.2016.1124856. Epub 2015 Dec 23. Expert Opin Pharmacother. 2016. PMID: 26605922 Review.
INTRODUCTION: Severe osteoporosis represents a disease of high mortality and morbidity. Recognition of what constitutes and causes severe osteoporosis and aggressive intervention with pharmacological agents with evidence to reduce fracture risk are outlined in this …
INTRODUCTION: Severe osteoporosis represents a disease of high mortality and morbidity. Recognition of what constitutes and causes se …
The epidemiology and management of postmenopausal osteoporosis: a viewpoint from Brazil.
Baccaro LF, Conde DM, Costa-Paiva L, Pinto-Neto AM. Baccaro LF, et al. Clin Interv Aging. 2015 Mar 20;10:583-91. doi: 10.2147/CIA.S54614. eCollection 2015. Clin Interv Aging. 2015. PMID: 25848234 Free PMC article. Review.
Postmenopausal osteoporosis is of particular concern because it leads to an increased risk of fractures, with subsequent negative impacts on health in older women. ...To reduce the risk of osteoporosis, all postmenopausal women should be encouraged to
Postmenopausal osteoporosis is of particular concern because it leads to an increased risk of fractures, with subsequent negat
Effects of pulsed electromagnetic fields on postmenopausal osteoporosis.
Zhu S, He H, Zhang C, Wang H, Gao C, Yu X, He C. Zhu S, et al. Bioelectromagnetics. 2017 Sep;38(6):406-424. doi: 10.1002/bem.22065. Epub 2017 Jun 30. Bioelectromagnetics. 2017. PMID: 28665487 Review.
Postmenopausal osteoporosis (PMOP) is considered to be a well-defined subject that has caused high morbidity and mortality. In elderly women diagnosed with PMOP, low bone mass and fragile bone strength have been proven to significantly increase risk of fragility fra
Postmenopausal osteoporosis (PMOP) is considered to be a well-defined subject that has caused high morbidity and mortality. In
Osteoporosis and fracture risk in older people.
Coughlan T, Dockery F. Coughlan T, et al. Clin Med (Lond). 2014 Apr;14(2):187-91. doi: 10.7861/clinmedicine.14-2-187. Clin Med (Lond). 2014. PMID: 24715132 Free PMC article. No abstract available.
Pathophysiology of osteoporosis: new mechanistic insights.
Armas LA, Recker RR. Armas LA, et al. Endocrinol Metab Clin North Am. 2012 Sep;41(3):475-86. doi: 10.1016/j.ecl.2012.04.006. Epub 2012 Jun 9. Endocrinol Metab Clin North Am. 2012. PMID: 22877425 Review.
Understanding of the pathophysiology of osteoporosis has evolved to include compromised bone strength and skeletal fragility caused by several factors: (1) defects in microarchitecture of trabeculae, (2) defective intrinsic material properties of bone tissue, (3) defective …
Understanding of the pathophysiology of osteoporosis has evolved to include compromised bone strength and skeletal fragility caused b …
Exercise Early and Often: Effects of Physical Activity and Exercise on Women's Bone Health.
Troy KL, Mancuso ME, Butler TA, Johnson JE. Troy KL, et al. Int J Environ Res Public Health. 2018 Apr 28;15(5):878. doi: 10.3390/ijerph15050878. Int J Environ Res Public Health. 2018. PMID: 29710770 Free PMC article. Review.
In 2011 over 1.7 million people were hospitalized because of a fragility fracture, and direct costs associated with osteoporosis treatment exceeded 70 billion dollars in the United States. ...Bone structure and quality will be discussed, especially in the context of clinic …
In 2011 over 1.7 million people were hospitalized because of a fragility fracture, and direct costs associated with osteoporosis trea …
Osteoporosis.
Lane JM, Russell L, Khan SN. Lane JM, et al. Clin Orthop Relat Res. 2000 Mar;(372):139-50. doi: 10.1097/00003086-200003000-00016. Clin Orthop Relat Res. 2000. PMID: 10738423 Review.
Osteoporosis is a disorder of decreased bone mass, microarchitectural deterioration, and fragility fractures. Osteoporosis is widespread and can affect people of all ethnic backgrounds and many older women and men. ...Major risk factors leading to fragility fracture
Osteoporosis is a disorder of decreased bone mass, microarchitectural deterioration, and fragility fractures. Osteoporosis is
Drugs for postmenopausal osteoporosis.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2017 Dec 18;59(1536):203-210. Med Lett Drugs Ther. 2017. PMID: 29232356 No abstract available.
Osteoporosis in menopause.
Khan A, Fortier M; MENOPAUSE AND OSTEOPOROSIS WORKING GROUP. Khan A, et al. J Obstet Gynaecol Can. 2014 Sep;36(9):839-840. doi: 10.1016/S1701-2163(15)30489-8. J Obstet Gynaecol Can. 2014. PMID: 25222365 English, French.
OBJECTIVE: To provide guidelines for the health care provider on the prevention, diagnosis, and clinical management of postmenopausal osteoporosis. OUTCOMES: Strategies for identifying and evaluating high-risk individuals, the use of bone mineral density (BMD) and b …
OBJECTIVE: To provide guidelines for the health care provider on the prevention, diagnosis, and clinical management of postmenopausal
Abaloparatide: A new pharmacological option for osteoporosis.
Sleeman A, Clements JN. Sleeman A, et al. Am J Health Syst Pharm. 2019 Jan 25;76(3):130-135. doi: 10.1093/ajhp/zxy022. Am J Health Syst Pharm. 2019. PMID: 30689744 Review.
Published articles pertinent to the short- and long-term efficacy and safety of abaloparatide among postmenopausal women with osteoporosis were reviewed and summarized. ...CONCLUSION: Abaloparatide is an effective anabolic agent to improve bone formation and resorpt …
Published articles pertinent to the short- and long-term efficacy and safety of abaloparatide among postmenopausal women with oste
90,024 results
Jump to page
Feedback